| Autor: |
Eilender, David, LoRusso, Patricia, Thomas, Leonard, McCormick, Catherine, Rodgers, Andrew H., Hooper, Catherine L., Tornyos, Karl, Krementz, Edward T., Parker, Steven, Morgan, Lee Roy |
| Předmět: |
|
| Zdroj: |
Cancer Chemotherapy & Pharmacology; Jun2006, Vol. 57 Issue 6, p719-726, 8p, 4 Color Photographs, 5 Charts |
| Abstrakt: |
Purpose: This study is to document the activity and acceptability for a new topical agent, A-007, in the treatment of cutaneous metastases from cancer. Patients and methods: This is a multicenter study involving 27 patients with inoperable skin lesions from histologically confirmed cancers of the breast and oral cavity, non-Hodgkin’s lymphoma, Kaposi’s sarcoma, and angiosarcoma that had failed radiotherapy or systemic treatment. A-007, as a 0.25% gel, was applied twice daily to the areas of cancer to be measured as well as applied to a healthy control area distant from the cancer areas. An untreated cancer area was also included and documented as a cancer control. Results: The overall objected response rate with A-007 was 26%, with an additional 19% minimum response/stabilization of cancer. For patients with breast cancer, hormonal status did not have an impact on response. The median duration of response was 15 weeks (with one patient having a response for 3.5 years). Toxicities observed were itching, burning, and a rash, in 6 of the 27 patients. The skin toxicities were in the cancer-treated fields; none were observed in the A-007 control areas. All irritated areas cleared while continuing treatment, and the tumor lesions in the areas of itching also improved. Conclusion: A-007, as a 0.25% gel, is confirmed as an effective palliative treatment option for cutaneous metastases from cancers. Skin reactions were minimal, tolerated, and no cessation of treatment was required. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink